Immune checkpoint inhibitors (ICIs), a powerful form of immunotherapy, have revolutionized cancer treatment by unleashing the ...

Johnson & Johnson delivered a "beat and raise" quarter. Results were bolstered by the new acquisition of Intra-Cellular, ...

Some of the most high-profile acquisitions in recent years have involved women-fronted biotechs. BioSpace reviews five of the ...

The FDA has eliminated a safety monitoring requirement and eased certain restrictions that had been in place since CAR T-therapies first reached the market in 2017. The agency and financial ...

FDA approved label changes for Breyanzi and Abecma, easing access by reducing monitoring rules and eliminating REMS safety program requirements.

Dr. Andre Henri Goy shared how CAR T-cell therapy led a retired pilot with lymphoma into remission, showing the impact of personalized treatment decisions.

CAR T-cell therapy has the potential to revolutionise how we treat certain types of cancer by genetically engineering someone’s own immune cells to attack the disease – but it is also ...

In the episode, we’re talking about vector design and delivery for gene therapies. The field of cell and gene therapies is advancing, but there are still challenges with delivery vectors that ...

The promise of stem cell therapy is powerful. Scientists can draw versatile cells from the human body and deliver them to repair injuries and fight disease from the inside out. But not all stem ...